Zai Lab Limited (NASDAQ:ZLAB) Shares Sold by Raymond James & Associates

Raymond James & Associates decreased its position in shares of Zai Lab Limited (NASDAQ:ZLAB) by 27.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,674 shares of the company’s stock after selling 5,200 shares during the quarter. Raymond James & Associates’ holdings in Zai Lab were worth $374,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Zai Lab in the 4th quarter valued at $116,000. WealthPlan Investment Management LLC grew its stake in Zai Lab by 81,968.8% in the 3rd quarter. WealthPlan Investment Management LLC now owns 39,393 shares of the company’s stock valued at $958,000 after acquiring an additional 39,345 shares during the period. Rock Springs Capital Management LP grew its stake in Zai Lab by 1.2% in the 3rd quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock valued at $30,072,000 after acquiring an additional 14,600 shares during the period. Lansdowne Partners UK LLP acquired a new stake in Zai Lab in the 3rd quarter valued at $854,000. Finally, Alps Advisors Inc. grew its stake in Zai Lab by 3.2% in the 3rd quarter. Alps Advisors Inc. now owns 72,842 shares of the company’s stock valued at $1,771,000 after acquiring an additional 2,263 shares during the period. Institutional investors and hedge funds own 41.65% of the company’s stock.

Insider Transactions at Zai Lab

In other news, insider Joshua L. Smiley sold 1,988 shares of Zai Lab stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the transaction, the insider now owns 28,684 shares in the company, valued at approximately $449,478.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Joshua L. Smiley sold 1,988 shares of Zai Lab stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the transaction, the insider now owns 28,684 shares in the company, valued at approximately $449,478.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rafael Amado sold 2,544 shares of Zai Lab stock in a transaction on Friday, March 15th. The stock was sold at an average price of $18.86, for a total value of $47,979.84. Following the transaction, the insider now owns 20,093 shares in the company, valued at approximately $378,953.98. The disclosure for this sale can be found here. Insiders have sold a total of 12,568 shares of company stock worth $208,508 in the last quarter. Company insiders own 5.23% of the company’s stock.

Zai Lab Stock Up 1.1 %

Shares of ZLAB opened at $15.91 on Friday. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.50. The firm’s fifty day moving average is $17.45 and its two-hundred day moving average is $22.57. The stock has a market cap of $1.58 billion, a PE ratio of -4.61 and a beta of 1.10.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.11). Zai Lab had a negative return on equity of 37.07% and a negative net margin of 125.46%. The business had revenue of $65.83 million for the quarter, compared to analyst estimates of $70.41 million. As a group, research analysts anticipate that Zai Lab Limited will post -3.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Citigroup dropped their price target on shares of Zai Lab from $123.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Friday, January 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zai Lab presently has a consensus rating of “Buy” and a consensus price target of $64.22.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.